Table 1.

Baseline characteristics

Baseline characteristics	Mean	SD	N
Age at MS diagnosis (in years)	33.9	11.8	40
Age at first consultation (in years)	42.1	11.0	40
Age at start of VD supplementation (in years)	44.1	11.0	40
EDSS score at start of VD supplementation	3.1	1.5	39
VD dose (in international units/week)	18,950	3,397	40
Gender	%		N
Female	60	—	24
MS phenotype	%		N
RRMS	75	—	30
PRMS	25	—	10

	Before VD	During VD	p‐value
Additional information
Serum 25(OH)D3 levels (mean (SD) (in nmol/L)), n = 26a	38.7 (24.1)	90.1 (27.1)	<.001b
Time of follow up (mean (SD) (in years)), n = 40	2.0 (1.4)	2.6 (1.2)	n.s.b
Immunotherapy
Interferons	35%	30%	n.s.c
No therapy	30%	22.5%	n.s.c
Glatiramer acetate	17.5%	20%	n.s.c
Natalizumab	10%	17.5%	n.s.c
Immunosuppressants	5%	2.5%	n.s.c
Glucocorticoids	2.5%	2.5%	n.s.c
Dimethyl fumarate	0%	5%	n.s.c

EDSS, Expanded disability status scale; MS, Multiple sclerosis; n.s., Nonsignificant; PR, Progressive relapsing; RR, Relapsing remitting; VD, Vitamin D; 25(OH)D₃, 25‐hydroxyvitamin D₃.

^aIncluded were only patients with available 25(OH)D₃ measurements before and during VD supplementation.

^bWilcoxon signed‐rank test.

^cChi‐square.